However, the addition of intraoperative MMC in combination with amniotic membrane improved the recurrence rate to 5.8% for an average follow-up period of 17 months. 14 MMC is an antimetabolite that inhibits pterygium cell proliferation and migration. 15 The medication has been widely studied as an adjuvant in pterygium surgery, with earlier reports on scleral melting ranging from 3% to 19%. 9 This could be significantly lowered with acceptable recurrence rates when a standard defined protocol is applied, even without simultaneous conjunctival grafting. 16 Long-term data on this regime also confirmed its safety at 10 years. 5 In addition to preservation of surrounding healthy conjunctiva, the duration of operation is also shorter than in situations where harvesting conjunctival graft is needed, particularly if sutures are required to secure the grafts instead of fibrin glue and in the hands of less experienced surgeons or surgical trainees.
Subconjunctival administration of anti-vascular endothelial growth factor (anti-VEGF) as an adjuvant in pterygium surgery has been evaluated in a handful of meta-analyses with conflicting conclusions. 17, 18 Despite the overall reasonable safety of bevacizumab, better designed clinical trials evaluating the efficacy of anti-VEGF are warranted. In addition, the relative high costs of anti-VEGF may be a prohibitive factor in less affluent economies or practices.
A recent strategy in pterygium surgery would include the use of mini-simple limbal epithelial transplant (mini-SLET). The initial technique of SLET was developed to treat unilateral limbal stem cell failure 19 ; an adaptation of this technique has been applied to other ocular surface conditions such as ocular surface squamous neoplasia and pterygium. A few published studies evaluated the use of mini-SLET or SLET in pterygium surgery with promising results. [20] [21] [22] More data from larger studies and preferably controlled trials should be conducted so as to evaluate the merits of this technique.
In conclusion, there is yet to be a panacea in treating pterygium. The remarks by Phathanthurarux and Chantaren highlighted the importance for surgeons to appreciate the potential complications of each of the treatment modality and the need to gain proficient experience with various approaches. Only then will one be able to lead a discussion with the patient and to decide on an agreed appropriate treatment plan for that particular individual. This can be facilitated through enhanced education and training, perhaps in better design of fellowship programs and/or local or regional surgical courses, to disseminate the knowledge and experience to the much needed areas. Armed with the appropriate knowledge and expertise, we will then have a fair chance in purging the plight of recurrence in pterygium surgery.
